Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2211-2220

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Arimoto, Akira ^a   Kita, Ryuichi ^a   Kimura, Toru ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Curative therapy; Hepatitis B core antigen antibody; Non B non C hepatocellular carcinoma; Overall survival; Recurrence free survival

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DECARBOXYPROTHROMBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN;

ABLATION THERAPY; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NON B NON C HEPATOCELLULAR CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SYSTEMIC THERAPY;

CURATIVE THERAPY; HEPATITIS B CORE ANTIGEN ANTIBODY; NON-B NON-C HEPATOCELLULAR CARCINOMA; OVERALL SURVIVAL; RECURRENCE-FREE SURVIVAL;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878185819     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Livraghi T, Makisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 100: 22-29, 2011.
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
3. de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol 56(Suppl 1): S75-S87, 2012.
4. Kaibori M, Ishizaki M, Matsui K and Kwon AH: Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg 204: 300-307, 2012.
5. Yotsuyanagi H, Shintani Y, Moriya K, Fujie H, Tsutsumi T, Kato T, Nishioka K, Takayama T, Makuuchi M, Iino S, Kimura S and Koike K: Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: Frequent involvement of hepatitis B virus. J Infect Dis 181: 1920-1928, 2000. (Pubitemid 30416153)
6. Utsunomiya T and Shimada M: Molecular characteristics of noncancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 41: 711-721, 2011.
7. Umemura T and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 37(Suppl 2): S95-S100, 2007.
8. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY and Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surgery 249: 195-202, 2009.
9. Nishikawa H, Osaki Y, Kita R, Kimura T, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S and Nasu A: Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 41: 903-909, 2012.
10. Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T and Omata M: Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. J Viral Hepat 17: 91-97, 2010.
11. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D and Raimondo G: Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 106: 1326-1330, 2006. (Pubitemid 43363910)
12. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T and Chiba T: Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carci-noma: A prospective study. Ann Intern Med 146: 649-656, 2007. (Pubitemid 351650520)
13. Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N, Suzuki F, Suzuki Y, Arase Y and Kumada H: Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: A cohort study. J Viral Hepat 16: 437-443, 2009.
14. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M and Morgan TR; HALT-C Trial Group: Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 54: 434-442, 2011.
15. Shiota G, Oyama K, Udagawa A, Tanaka K, Nomi T, Kitamura A, Tsutsumi A, Noguchi N, Takano Y, Yashima K, Kishimoto Y, Suou T and Kawasaki H: Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: Involvement of HBx and p53. J Med Virol 62: 151-158, 2000.
16. Jilg W, Sieger E, Zachoval R and Schatzl H: Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus. J Hepatol 23: 14-20, 1995.
17. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME and Raimondo G: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341: 22-26, 1999. (Pubitemid 29293716)
18. Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, Chevallier P, Mandrand B and Trépo C: High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 34: 447-454, 2001. (Pubitemid 32240826)
19. Shintani Y, Yotsuyanagi H, Moriya K, Fujie H, Tsutsumi T, Takayama T, Makuuchi M, Kimura S and Koike K: The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer 88: 2478-2486, 2000. (Pubitemid 30331953)
20. Kusakabe A, Tanaka Y, Orito E, Sugauchi F, Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T, Ueda R and Mizokami M: A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 42: 298-305, 2007. (Pubitemid 46681705)
21. Tamori A, Nishiguchi S, Kubo S, Narimatsu T, Habu D, Takeda T, Hirohashi K and Shiomi S: HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 71: 492-498, 2003. (Pubitemid 37309918)
22. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P and Patt YZ: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36: 1206-1213, 2002. (Pubitemid 35253437)
23. Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus- provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998. (Pubitemid 28319935)
24. Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
25. Liver Cancer Study Group of Japan: The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 19: 98-129, 1989.
26. Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, Kudo M, Yamamoto Y, Kojima H, Seno H, Moriyasu F and Chiba T: High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus-related chronic liver disease in Japan. Gut pp. 45284-45288, 1999.
27. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K and Chiba T: Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology pp. 31488-31495, 2000.
28. Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y and Kumada H: High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 115: 571-580, 2009.
29. Lautz HU, Selberg O, Korber J, Burger M and Muller MJ: Protein-calorie malnutrition in liver cirrhosis. Clin Investig 70: 478-486, 1992.
30. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis: Nutritional status in cirrhosis. J Hepatology 21: 317-335, 1994.
31. Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S, Kita R and Kimura T: Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 18: 1379-1384, 2012.
32. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H and Kumada H: Large-scale long-term follow-up study of Japanese patients with nonalcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 107: 253-261, 2012.